Commercially available mRNA vaccines against COVID have been shown to train patients’ immune systems to kill cancer cells. Combining these vaccines with standard-of-care immune therapy overwhelms tumour defences and is associated with improved survival, both in animal models and in large cohorts of people with cancer.